Three stories about the world of opioids collide: a drug trafficker arranges a multi-cartel Fentanyl smuggling operation between Canada and the U.S., an architect recovering from an OxyContin addiction tracks down the truth behind her son's involvement with narcotics, and a university professor battles unexpected revelations about his research employer, a drug company with deep government influence bringing a new "non-addictive" painkiller to market.
Lisa Conroy is general manager at a highway-side 'sports bar with curves', Double Whammies. She nurtures and protects her employees fiercely - but over the course of one trying day, her optimism is battered from every direction... Double Whammies sells a big, weird American fantasy, but what happens when reality pokes a bunch of holes in it?
A young, hipster entrepreneur crashes and burns on the eve of his company’s big launch. With his entire life in disarray, he leaves Manhattan to move in with his estranged pregnant sister, brother-in-law and three year-old nephew in the suburbs — only to become their manny. Faced with real responsibility, he may finally have to grow up — but not without some bad behavior first.
On the eve of the admissions cycle for New York City kindergartens, Alex and Greg Wheeler have high hopes for four-year-old Jake. The director of Jake's preschool encourages them to accentuate Jake's gender expansive behavior to help him stand out. As Alex and Greg navigate their roles as parents, a rift grows between them, one that forces them to confront their own concerns about what's best for Jake, and each other.
Over the course of a summer, two teenage girls develop the perfect kindred spirit friendship, with one big problem: one of them is dating the other's ex.
Three stories about the world of opioids collide: a drug trafficker arranges a multi-cartel Fentanyl smuggling operation between Canada and the U.S., an architect recovering from an OxyContin addiction tracks down the truth behind her son's involvement with narcotics, and a university professor battles unexpected revelations about his research employer, a drug company with deep government influence bringing a new "non-addictive" painkiller to market.